Skip to main content

Table 2 Risk factors for the development of drug resistance to Mycobacterium tuberculosis as reported by Wilson and Tsukayama [4]

From: Rare presentation of intractable tuberculous panophthalmitis with intraocular and intraorbital abscesses: a case report

Previous treatment for Mtb

Prolonged hospitalization (in Mtb-endemic regions)

human immunodeficiency virus coinfection

Inappropriate prescribing of combination ATT (incorrect drug selection, dosing, and improper dispensing)

Lack of directly observed therapy use during therapy and subsequent patient noncompliance with prescribed therapy

Lack of sustainable drug availability to patients (for example, second-line drugs for drug-resistant tuberculosis) through an inadequate pharmaceutical supply chain or failure to provide free treatment

Overuse of fluoroquinolones in other non-Mtb respiratory infection syndromes that propagates fluoroquinolone-resistant Mtb

Delays in diagnosing drug-resistant Mtb

  1. Abbreviations: Mtb Mycobacterium tuberculosis, ATT Antituberculous therapy
Back to article page

Journal of Medical Case Reports

ISSN: 1752-1947